LEASES (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 9 Months Ended | ||||
|---|---|---|---|---|---|---|---|
Jul. 25, 2024 |
Aug. 31, 2026 |
Sep. 30, 2026 |
Sep. 30, 2025 |
Sep. 30, 2026 |
Sep. 30, 2025 |
Dec. 31, 2025 |
|
| Lessee, Lease, Description [Line Items] | |||||||
| Operating lease right-of-use assets | $ 164,115 | $ 164,115 | $ 23,360 | ||||
| Right-of-use asset obtained in exchange for operating lease liability | $ 167,967 | ||||||
| Operating lease, option to extend | In August 2026, the Company exercised its option under its existing office sublease with Saptalis Pharmaceuticals, LLC, which commenced on October 1, 2023, with an initial term ending July 31, 2026, to extend the term for an additional five years through August 31, 2031. Monthly rent during the extended term is $3,600 for the first 12 months, increasing 4% annually beginning August 1, 2027. | ||||||
| Monthly rent | $ 3,600 | ||||||
| Weighted-average discount rate | 15.50% | 15.50% | 15.50% | ||||
| Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense | |||||||
| Lessee, Lease, Description [Line Items] | |||||||
| Operating lease expense | $ 11,338 | $ 8,906 | $ 25,077 | $ 68,103 | |||
| Merger Agreement [Member] | Scienture Inc [Member] | |||||||
| Lessee, Lease, Description [Line Items] | |||||||
| Operating lease right-of-use assets | $ 61,578 | ||||||
| Right-of-use asset obtained in exchange for operating lease liability | $ 61,886 | ||||||